UGN-101 Reviewed in Real-World Upper Tract Urothelial Cancer Setting
For patients with low-grade residual disease, complete response rate was 70 percent with UGN-101
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.